FDA Issues Draft Guidance On Advisory Panel Conflict Disclosures
This article was originally published in The Gray Sheet
Executive Summary
FDA's issued a 1draft guidance Oct. 31 clarifying its process for publicizing FDA advisory panel members' potential conflicts-of-interest
You may also be interested in...
FDA Works To Fill Panel Vacancies While Tightening Conflict Rules
FDA is working on an initiative to fill up to two-thirds of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies
FDA Works To Fill Panel Vacancies While Tightening Conflict Rules
FDA is working on an initiative to fill up to two-thirds of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies
With Five Guidances, FDA Overhauls Its Advisory Committee Policies
FDA should hold voluntary advisory committee meetings only for matters that are of significant public interest or controversy, or that demand unique expertise, the agency's Office of Policy, Planning and Preparedness says in a 1draft guidance released Aug. 5